PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$5.42−0.15 (-2.69%)
Close on Nov 17, 2026Market cap $58.19MP/E –Yield –
PharmaCyte Biotech pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
PharmaCyte Biotech's pe ratio was 0.3× on May 29, 2026, against 1.3× a year earlier. Over the last 2 years it ranged from 0.2× to 47.2×, with a median of 1.3×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | May 29, 2026 | 0.3× | +0.1 |
| 2025 | Dec 31, 2025 | 0.2× | −2.6 |
| 2024 | Dec 31, 2024 | 2.8× | – |
See a number that looks wrong?